1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Fibrosis - Drugs In Development, 2022, provides an overview of the Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors and exposure to chemicals or radiation. Symptoms include pain, problems related to urination, nausea and vomiting. The condition may be managed with medication and kidney transplant.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Kidney Fibrosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Kidney Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 37 and 9 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 1 molecules, respectively.
Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Fibrosis (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Kidney Fibrosis - Overview
- Kidney Fibrosis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Kidney Fibrosis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Kidney Fibrosis - Companies Involved in Therapeutics Development
- Kidney Fibrosis - Drug Profiles
- Kidney Fibrosis - Dormant Projects
- Kidney Fibrosis - Discontinued Products
- Kidney Fibrosis - Product Development Milestones
- Featured News & Press Releases
- Jul 04, 2022: AD-214 program modified to maximise partnering options, extends cash runway
- Jan 04, 2022: Alentis Therapeutics starts first-in-human clinical trial for the treatment of liver and kidney fibrosis
- Sep 27, 2021: AdAlta announces new preclinical data presented at “Discovery on Target” meeting
- Sep 08, 2021: RedHill’s opaganib reduces kidney fibrosis in preclinical study
- Jun 22, 2020: Hepion Pharmaceuticals' CRV431 demonstrates efficacy in kidney fibrosis
- Nov 11, 2019: Liminal Biosciences presents new preclinical data on PBI-4610 at ASN Kidney Week 2019
- Oct 24, 2019: Liminal BioSciences announces upcoming presentation on drug candidate PBI-4610 at ASN kidney week 2019
- Jul 18, 2019: Genkyotex to launch Phase II pulmonary fibrosis trial in US
- Jan 14, 2019: Nash Pharmaceuticals provides update on Kidney Disease drug candidate NP-160
- Jan 14, 2019: Nash Pharmaceuticals Announces Positive Pre-Clinical Results From a Second Study for Chronic Kidney Disease
- Nov 29, 2018: Kadmon presents data on New ROCK Inhibitor clinical candidate at Anti-Fibrotic Drug Development Summit
- Nov 19, 2018: Nash Pharmaceuticals announces positive pre-clinical results for its lead compound NP-135 in chronic kidney disease
- Aug 30, 2018: VBL Therapeutics announces publication of positive new data on its Lecinoxoid drug candidates for the treatment of renal fibrosis
- Nov 13, 2017: AdAlta to present at Anti-Fibrotic Drug Development Summit in Boston
- Sep 06, 2017: Pharmaxis Announces Anti Fibrotic LOXL2 Program Clears Preclinical Development And Set To Commence Phase 1 Trials
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Kidney Fibrosis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Companies, 2022 (Contd..1)
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Products under Development by Companies, 2022 (Contd..2)
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Target, 2022 (Contd..1)
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Kidney Fibrosis - Pipeline by Accendatech Co Ltd, 2022
- Kidney Fibrosis - Pipeline by AdAlta Ltd, 2022
- Kidney Fibrosis - Pipeline by Alentis Therapeutics AG, 2022
- Kidney Fibrosis - Pipeline by Algernon Pharmaceuticals Inc, 2022
- Kidney Fibrosis - Pipeline by Anagenics Ltd, 2022
- Kidney Fibrosis - Pipeline by Angion Biomedica Corp, 2022
- Kidney Fibrosis - Pipeline by AstraZeneca Plc, 2022
- Kidney Fibrosis - Pipeline by BiOrion Technologies BV, 2022
- Kidney Fibrosis - Pipeline by CohBar Inc, 2022
- Kidney Fibrosis - Pipeline by Epigen Biosciences Inc, 2022
- Kidney Fibrosis - Pipeline by Evotec SE, 2022
- Kidney Fibrosis - Pipeline by Future Medicine Co Ltd, 2022
- Kidney Fibrosis - Pipeline by Galapagos NV, 2022
- Kidney Fibrosis - Pipeline by Galectin Therapeutics Inc, 2022
- Kidney Fibrosis - Pipeline by GenKyoTex SA, 2022
- Kidney Fibrosis - Pipeline by Hepion Pharmaceuticals Inc, 2022
- Kidney Fibrosis - Pipeline by iBio Inc, 2022
- Kidney Fibrosis - Pipeline by InSilico Medicine, 2022
- Kidney Fibrosis - Pipeline by Isarna Therapeutics GmbH, 2022
- Kidney Fibrosis - Pipeline by Jiangxi Jemincare Group Co Ltd, 2022
- Kidney Fibrosis - Pipeline by Kadmon Holdings Inc, 2022
- Kidney Fibrosis - Pipeline by Liminal BioSciences Inc, 2022
- Kidney Fibrosis - Pipeline by Max Biopharma Inc, 2022
- Kidney Fibrosis - Pipeline by Mission Therapeutics Ltd, 2022
- Kidney Fibrosis - Pipeline by NB Health Laboratory Co Ltd, 2022
- Kidney Fibrosis - Pipeline by Novo Nordisk AS, 2022
- Kidney Fibrosis - Pipeline by Osteoneurogen Inc, 2022
- Kidney Fibrosis - Pipeline by Pharmaxis Ltd, 2022
- Kidney Fibrosis - Pipeline by RedHill Biopharma Ltd, 2022
- Kidney Fibrosis - Pipeline by Rubedo Life Sciences Inc, 2022
- Kidney Fibrosis - Pipeline by Sanofi, 2022
- Kidney Fibrosis - Pipeline by Scholar Rock Inc, 2022
- Kidney Fibrosis - Pipeline by Secarna Pharmaceuticals GmbH & Co KG, 2022
- Kidney Fibrosis - Pipeline by Senolytic Therapeutics Inc, 2022
- Kidney Fibrosis - Pipeline by TRACON Pharmaceuticals Inc, 2022
- Kidney Fibrosis - Pipeline by Transcenta Holding Ltd, 2022
- Kidney Fibrosis - Pipeline by UCB SA, 2022
- Kidney Fibrosis - Pipeline by Vascular Biogenics Ltd, 2022
- Kidney Fibrosis - Pipeline by Vectus Biosystems Ltd, 2022
- Kidney Fibrosis - Dormant Projects, 2022
- Kidney Fibrosis - Dormant Projects, 2022 (Contd..1)
- Kidney Fibrosis - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Kidney Fibrosis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Accendatech Co Ltd
- AdAlta Ltd
- Alentis Therapeutics AG
- Algernon Pharmaceuticals Inc
- Anagenics Ltd
- Angion Biomedica Corp
- AstraZeneca Plc
- BiOrion Technologies BV
- CohBar Inc
- Epigen Biosciences Inc
- Evotec SE
- Future Medicine Co Ltd
- Galapagos NV
- Galectin Therapeutics Inc
- GenKyoTex SA
- Hepion Pharmaceuticals Inc
- iBio Inc
- InSilico Medicine
- Isarna Therapeutics GmbH
- Jiangxi Jemincare Group Co Ltd
- Kadmon Holdings Inc
- Liminal BioSciences Inc
- Max Biopharma Inc
- Mission Therapeutics Ltd
- NB Health Laboratory Co Ltd
- Novo Nordisk AS
- Osteoneurogen Inc
- Pharmaxis Ltd
- RedHill Biopharma Ltd
- Rubedo Life Sciences Inc
- Sanofi
- Scholar Rock Inc
- Secarna Pharmaceuticals GmbH & Co KG
- Senolytic Therapeutics Inc
- TRACON Pharmaceuticals Inc
- Transcenta Holding Ltd
- UCB SA
- Vascular Biogenics Ltd
- Vectus Biosystems Ltd
